New research reveals that patients who discontinue new slimming jabs like Mounjaro or Wegovy may regain shed pounds far faster than those who end traditional diet and exercise regimens.
Published data in a prominent health publication shows that while obese people can lose a large proportion of their total mass while on the medication, the weight comes back at an estimated rate of 0.8 kg per month after stopping.
"Users purchasing these treatments should be cognizant of the risk of quick weight regain when the therapy is stopped," warns researcher Dr. Susan Jebb.
Such speed of regain implies a return to original mass within about 18 months.
Weighing Approaches
The analysis, which examined dozens of trials involving thousands of participants, compared the effects of these new drugs with older methods.
The team point out that people who shed pounds through dieting typically have a more gradual creep back—around 0.1 kg a month—after stopping.
Understanding the Quick Rebound
Nutrition scientists suggest the way of the drugs accounts for the amplified regain.
These medications mimic a natural hormone called glucagon-like peptide-1, which controls appetite.
"Sustained high doses of the hormone concentrations several times higher than normal might result in the system to generate a reduced amount of its own natural GLP-1, and could diminish sensitivity to its effects," explained Dr. Adam Collins, a nutrition specialist.
"Discontinuation of this GLP-1 'fix' leads to hunger is unsuppressed, making overeating far more likely."
A Chronic Issue?
The NHS recommend the jabs for individuals with obesity-related medical conditions, alongside prescribed lifestyle changes.
Professionals say that, given the high risk of relapse, the treatment might need to be ongoing.
This perspective is reinforced by pharmaceutical companies, who say that the results "emphasize the persistent character of excess weight," similar to managing diseases like high blood pressure.
User Accounts
Users who have come off the medication explain a powerful resurgence of appetite.
"It was like a trigger flipping and I was suddenly ravenous," recalled one woman.
This difficulty is compounded if users have not adopted lasting lifestyle or habit modifications during therapy.
Widespread Adoption
Recent estimates indicate that a significant number of people in the UK have used weight-loss jabs in the last 12 months, with demand being substantial.
- Adoption is more common among females compared to men.
- The middle-aged demographic shows the highest usage rates.
- A large proportion obtain the drugs through private healthcare rather than the NHS.
Finally, experts emphasize that while GLP-1 drugs are potent tools for weight loss, they are not a magic fix and lasting health benefits hinges on ongoing behavioural support.
